Abstract
Nebuliser therapy is a relevant therapy option for respiratory diseases, yet studies have demonstrated a wide variation in nebuliser drug delivery efficiency. This study assessed the aerosol performance of 15 commercially available nebuliser systems based on a European standard, and calculated the respirable drug delivery rate (RDDR) as an objective, clinically important measure of efficiency. Findings confirmed that the efficiency of nebuliser systems differs significantly, which could potentially impact the therapeutic success of the drug delivered. The authors of the study recommend that physicians select a device with a high RDDR to ensure that patients receive clinically effective doses in a short time and thus achieve the best possible treatment effect.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
